Moleculin Biotech (MBRX) Total Liabilities (2015 - 2026)
Moleculin Biotech (MBRX) posted quarterly Total Liabilities of $7.1 million for Q4 2025, up 24.54% year-over-year from $5.7 million in Q4 2024, and down 84.94% quarter-over-quarter from $47.3 million in Q3 2025.
Moleculin Biotech (MBRX) Total Liabilities (2015 - 2026) Analysis & Trends
Moleculin Biotech's Total Liabilities history runs 11 years deep, the most recent figure standing at $7.1 million for Q4 2025.
- In Q4 2025, Total Liabilities rose 24.54% year-over-year to $7.1 million; the TTM figure through Dec 2025 stood at $7.1 million (up 24.54% YoY), while the FY2025 annual figure was $7.1 million, up 24.54% from the prior year.
- Total Liabilities for Q4 2025 stood at $7.1 million, down from $47.3 million in the prior quarter.
- The five-year high for Total Liabilities was $47.3 million in Q3 2025, with the low at $4.4 million in Q3 2023.
- The 5-year median for Total Liabilities is $7.2 million (2025), against an average of $10.6 million.
- The sharpest annual moves came in 2021 and 2024: Total Liabilities tumbled 54.78% in 2021, then jumped 262.94% in 2024.
- Moleculin Biotech's Total Liabilities stood at $5.1 million in 2021, then grew by 2.63% to $5.2 million in 2022, then surged by 132.15% to $12.1 million in 2023, then sank by 52.92% to $5.7 million in 2024, then grew by 24.54% to $7.1 million in 2025.
- Business Quant data shows MBRX's Total Liabilities at $7.1 million in Q4 2025, $47.3 million in Q3 2025, and $25.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 10.03 Bn |
| 10 | Moleculin Biotech | 3.35 Mn | 3.35 Mn | - | 9.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.50 Mn |
| Dec 31, 2025 | 7.12 Mn |
| Sep 30, 2025 | 47.27 Mn |
| Jun 30, 2025 | 25.18 Mn |
| Mar 31, 2025 | 7.22 Mn |
| Dec 31, 2024 | 5.72 Mn |
| Sep 30, 2024 | 15.92 Mn |
| Jun 30, 2024 | 7.87 Mn |
| Mar 31, 2024 | 9.26 Mn |
| Dec 31, 2023 | 12.14 Mn |
| Sep 30, 2023 | 4.39 Mn |
| Jun 30, 2023 | 6.85 Mn |
| Mar 31, 2023 | 5.38 Mn |
| Dec 31, 2022 | 5.23 Mn |
| Sep 30, 2022 | 6.96 Mn |
| Jun 30, 2022 | 6.90 Mn |
| Mar 31, 2022 | 6.14 Mn |
| Dec 31, 2021 | 5.10 Mn |
| Sep 30, 2021 | 7.44 Mn |
| Jun 30, 2021 | 8.83 Mn |